Spots Global Cancer Trial Database for Trial of Motexafin Gadolinium and Pemetrexed (Alimta®) for Second Line Treatment in Patients With Non-Small Cell Lung Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Trial of Motexafin Gadolinium and Pemetrexed (Alimta®) for Second Line Treatment in Patients With Non-Small Cell Lung Cancer
Official Title: Phase II Trial of Motexafin Gadolinium and Pemetrexed (Alimta®) for Second Line Treatment in Patients With Non-Small Cell Lung Cancer
Study ID: NCT00365183
Conditions
Interventions
Study Description
Brief Summary: The goals of this study are: * to determine if the combination of two drugs, motexafin gadolinium and pemetrexed, may be an effective treatment for patients with non-small cell lung cancer (NSCLC) who have had one previous chemotherapy regimen that included a platinum containing drug such as cisplatin or carboplatin. * to assess response to treatment in patients with NSCLC six months after beginning study treatment.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
, Huntington Beach, California, United States
, Long Beach, California, United States
, Chicago, Illinois, United States
, Baltimore, Maryland, United States
, Minneapolis, Minnesota, United States
, St. Louis, Missouri, United States
, Albuquerque, New Mexico, United States
, Santa Fe, New Mexico, United States
, Armonk, New York, United States
, Columbus, Ohio, United States
, Seattle, Washington, United States
Contact Details
Name: Martin Edelman, MD
Affiliation: University of Maryland, Greenbaum Cancer Center
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
